Newscast – Page 114 – media

Why AstraZeneca’s New Drug Strategy Seems to be Bearing Fruit

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
- Source: china-pharmacy
- 515
- February 7, 2018
AstraZeneca New Drug Strategy
Drug Safety Communication – Boxed Warning Added To Highlight Correct Dosing

FDA is warning that the liver disease medicine Ocaliva (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (PBC), a rare chronic liver disease, increasing the risk of serious liver injury. To ensure correct dosing and reduce the risk of liver problems, FDA is clarifying the current recommendations for screening, dosing, monitoring, and managing PBC patients with moderate to severe liver disease taking Ocaliva. FDA is adding a new Boxed Warning, FDA’s most prominent warning, to highlight this information in the prescribing information of the drug label. FDA is also requiring a Medication Guide for patients to inform them about this issue.
- Source: fda
- 608
- February 6, 2018
Boxed Warning FDA liver disease Ocaliva PBC
Insightec closes $150m Series E

HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
- Source: drugdu
- 538
- February 6, 2018
Market Views MRgFUS non-invasive treatments
Ultrasound tech genetically controls cells to kill cancer new study finds

Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
- Source: Healthcare IT news
- 617
- February 6, 2018
cancer CAR–T immunotherapy Researches
Nicotine in E-cigarettes damages DNA, mouse study suggests

The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
- Source: medicalxpress
- 633
- February 6, 2018
cancer DNA e-cigarettes nicotine Researches
Edible QR medication could help doctors prescribe more accurately, keep patients more informed

It's not uncommon to see customers paying for coffee or boarding a flight using a QR code from their smartphone, but some researchers are now looking to create an edible medication QR code. Researchers at the University of Copenhagen recently published a study in the International Journal of Pharmaceutics which looks at creating QR-encoded smart oral medication made by inkjet printing.
- Source: MobiHealthNews
- 516
- February 6, 2018
digital health medtech mHealth Researches
Why healthcare cybersecurity spending will exceed $65B over the next 5 years

Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
- Source: CSO Online
- 593
- February 6, 2018
cybersecurity digital health Market Views
Prostate cancer now third biggest cancer killer in the UK

The number of men dying from prostate cancer has overtaken the number of women dying from breast cancer for the first time, with the disease now the UK’s third biggest cancer killer.
- Source: pharmatimes
- 536
- February 5, 2018
prostate cancer Researches
Breakthrough status for Roche’s autism drug

Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
- Source: pharmatimes
- 645
- February 5, 2018
ASD balovaptan New Approvals Roche
Ferring’s ZOMACTON® (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Deficiency in Adults

Administration (FDA) has approved ZOMACTON® (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
- Source: medindia.net
- 650
- February 5, 2018
FDA GH deficiency growth hormone ZOMACTON®

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.